SCHEMBL7206261

SCHEMBL7206261

COc1ccc(NS(=O)(=O)c2cccc(Cl)c2)cc1N1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 11/20 0.60
STS P08842 1/20 0.57
ALDH1A1 P00352 2/20 0.56
KMT2A Q03164 2/20 0.56
MAPT P10636 1/20 0.54
MAPK1 P28482 1/20 0.54
TGFBR1 P36897 5/20 0.53
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
HTR1A P08908 1/20 0.50
CYP2D6 P10635 1/20 0.50
DRD2 P14416 1/20 0.50
HTR1D P28221 1/20 0.50
HTR1B P28222 1/20 0.50
HTR2A P28223 1/20 0.50
HTR2C P28335 1/20 0.50
HTR1E P28566 1/20 0.50
HTR1F P30939 1/20 0.50
CYP2C19 P33261 1/20 0.50
HTR7 P34969 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7200576 0.89 HTR6 (0.58) HTR6ALDH1A1KMT2ATGFBR1CYP1A2
SCHEMBL1612319 0.86 HTR6 (0.54) HTR6ALDH1A1KMT2ATGFBR1CYP1A2
SCHEMBL6975334 0.85 HTR6 (0.82) HTR6ALDH1A1KMT2ACYP1A2CYP3A4
SCHEMBL855334 0.83 HTR6 (0.51) HTR6ALDH1A1KMT2ATGFBR1CYP1A2
SCHEMBL6980929 0.82 HTR6 (0.85) HTR6CYP1A2CYP3A4HTR1ACYP2D6
SCHEMBL7689845 0.81 HTR6 (0.49) HTR6STSALDH1A1KMT2AMAPT
SCHEMBL12632946 0.80 CYP2C9 (0.58) HTR6STSALDH1A1KMT2AMAPT
SCHEMBL7200046 0.80 HTR6 (0.76) HTR6CYP1A2CYP3A4HTR1ACYP2D6
SCHEMBL4212376 0.80 STS (0.55) HTR6STSMAPTTGFBR1HTR1A
SCHEMBL1612888 0.78 TGFBR1 (0.49) HTR6TGFBR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6599904-B2 5-HT6 receptor antagonists are believed to be of potential use in the treatment of certain CNS disorders; cognitive memory enhancement SMITHKLINE BEECHAM P.L.C. (GB) 2003-07-29 US disclosed
US-6423717-B1 NERVOUS SYSTEM DISORDERS SMITHKLINE BEECHAM P.L.C. (GB) 2002-07-23 US disclosed